|By Business Wire||
|June 11, 2014 04:05 PM EDT||
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day on June 19, 2014 at 12:30 p.m. EDT to discuss its next RNAi-based clinical candidate which targets a rare liver disease. A live webcast of the presentation and archive will be available on the Company’s website at www.arrowheadresearch.com. To access an audio only live presentation, dial 844-825-4406 toll free from the U.S. or 315-625-3230 for international callers and enter Conference ID 54600551.
During the event, a panel of disease area key opinion leaders will present information about the pathophysiology, patient populations, and current treatments for the disease. In addition, Arrowhead’s management will present nonclinical data and provide anticipated timelines for further development of the candidate.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to [email protected].
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Dec. 10, 2016 01:45 PM EST Reads: 608
Dec. 10, 2016 01:00 PM EST Reads: 370
Dec. 10, 2016 01:00 PM EST Reads: 1,233
Dec. 10, 2016 12:45 PM EST Reads: 2,134
Dec. 10, 2016 12:30 PM EST Reads: 1,965
Dec. 10, 2016 12:15 PM EST Reads: 7,460
Dec. 10, 2016 12:15 PM EST Reads: 2,279
Dec. 10, 2016 12:00 PM EST Reads: 777
Dec. 10, 2016 12:00 PM EST Reads: 1,083
Dec. 10, 2016 12:00 PM EST Reads: 2,398
Dec. 10, 2016 12:00 PM EST Reads: 2,408
Dec. 10, 2016 12:00 PM EST Reads: 484
Dec. 10, 2016 11:30 AM EST Reads: 2,021
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Dec. 10, 2016 11:00 AM EST Reads: 1,009
Dec. 10, 2016 11:00 AM EST Reads: 679